Value
9.6/10data confidence 40%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 9.1 |
- ▸Attractively valued
GLPG · Why this verdict
Why Galapagos (GLPG) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Galapagos NV has delivered three straight earnings beats and maintained gross margins of 47%, but a 91.4% year-over-year revenue decline and an operating margin of -982.9% signal severe business deterioration that makes any valuation argument fragile; the stock sits below its 200-day moving average with only 4% headroom to the price target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue has declined 91.4% year-over-year and the operating margin has compressed to -982.9%, signaling near-total erosion of the top line and raising value-trap risk that puts the investment case on a fragile foundation. Bear case | Revenue posts positive year-over-year growth for at least 2 consecutive quarters, providing the first evidence of stabilization after the severe contraction. | →Stable |
| CounterA biotech in strategic transition may report extreme revenue swings following a product divestiture or expiration of a large licensing agreement, meaning a single year's decline may not reflect the ongoing earnings power of the remaining pipeline. | ||
Despite the dramatic top-line contraction, gross margins have held at 47% and the net margin screens in the highest tier — an unusual signal that cost discipline remains intact even as revenue has compressed severely. Quality breakdown | Gross margin remains above 40% over the next four quarters, demonstrating that the cost structure is holding even as the company works to stabilize revenue. | →Stable |
| CounterFree cash flow covers only 43% of reported net income — flagged as a quality red alert — meaning the headline margin strength may not be translating into cash available to fund operations or reinvestment, which undermines the cost-discipline interpretation. | ||
Three of the most recent four quarters produced positive earnings surprises — including three consecutive beats running through the latest report — suggesting the business is managing costs or generating income ahead of depressed expectations even as revenue contracts. Earnings | The beat streak extends to at least five consecutive quarters, with positive surprises in each period validating that guidance discipline is durable. | →Stable |
| CounterIn a business with sharply declining revenue, beats against depressed estimates can reflect one-time items or cost cuts rather than durable operational improvement; the oldest result in the record was a miss of -599%, demonstrating how violently expectations can be breached when conditions shift. | ||
The stock is trading below its 200-day moving average with a flat slope, and a death cross signal — though described as recovering — flags that the long-term price trend has not yet turned constructive. Momentum breakdown | Price closes above the 200-day moving average and holds for at least 4 consecutive weeks, confirming a durable technical recovery and invalidating the downtrend concern. | →Stable |
| CounterMomentum has already improved to the point of recovering from the death cross condition, and volume accumulation is rising — both of which can precede a sustained price recovery before the moving average itself turns positive. | ||
Revenue has declined 91.4% year-over-year and the operating margin has compressed to -982.9%, signaling near-total erosion of the top line and raising value-trap risk that puts the investment case on a fragile foundation.
→StableBear case
- Expectation
- Revenue posts positive year-over-year growth for at least 2 consecutive quarters, providing the first evidence of stabilization after the severe contraction.
CounterA biotech in strategic transition may report extreme revenue swings following a product divestiture or expiration of a large licensing agreement, meaning a single year's decline may not reflect the ongoing earnings power of the remaining pipeline.
Despite the dramatic top-line contraction, gross margins have held at 47% and the net margin screens in the highest tier — an unusual signal that cost discipline remains intact even as revenue has compressed severely.
→StableQuality breakdown
- Expectation
- Gross margin remains above 40% over the next four quarters, demonstrating that the cost structure is holding even as the company works to stabilize revenue.
CounterFree cash flow covers only 43% of reported net income — flagged as a quality red alert — meaning the headline margin strength may not be translating into cash available to fund operations or reinvestment, which undermines the cost-discipline interpretation.
Three of the most recent four quarters produced positive earnings surprises — including three consecutive beats running through the latest report — suggesting the business is managing costs or generating income ahead of depressed expectations even as revenue contracts.
→StableEarnings
- Expectation
- The beat streak extends to at least five consecutive quarters, with positive surprises in each period validating that guidance discipline is durable.
CounterIn a business with sharply declining revenue, beats against depressed estimates can reflect one-time items or cost cuts rather than durable operational improvement; the oldest result in the record was a miss of -599%, demonstrating how violently expectations can be breached when conditions shift.
The stock is trading below its 200-day moving average with a flat slope, and a death cross signal — though described as recovering — flags that the long-term price trend has not yet turned constructive.
→StableMomentum breakdown
- Expectation
- Price closes above the 200-day moving average and holds for at least 4 consecutive weeks, confirming a durable technical recovery and invalidating the downtrend concern.
CounterMomentum has already improved to the point of recovering from the death cross condition, and volume accumulation is rising — both of which can precede a sustained price recovery before the moving average itself turns positive.
Per-dimension breakdown
Quality
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 5.4 |
| ROA | 7.1 |
| Gross margin | 6.8 |
| Net margin | 10.0 |
| Current ratio | 5.0 |
| FCF quality | 3.5 |
| Moat | 6.6 |
| Piotroski F | 6.7 |
- ▸Strong margins: 47%
- ▸Earnings quality RED FLAG: 43% FCF/NI
Growth
5.0/10data confidence 50%Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 7.6 |
| OBV | 10.0 |
| MA position | 1.5 |
| Volume | 9.9 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 4.6 |
| erm sentiment | 5.0 |
Insider
5.0/10data confidence 50%Peer rank
6.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.7 |
| quality rank | 8.7 |
| growth rank | 0.3 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.5 |
| support resistance | 7.5 |
| 52w position | 4.7 |
Risk (lower is worse)
5.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 8.3 |
| days to cover | 3.4 |
| volatility | 7.0 |
| put call | 0.0 |
| implied vol | 2.3 |
| debt equity | 9.2 |
- ▸Elevated put/call: 8.00
- ▸High IV: 66%
Catalyst
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (7)
- MOMENTUM:6.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-3.4=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=6.5>=5.0 recovering
Reward-to-Risk
-3.41
Upside
-17.0%
Downside
5.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.9B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.5>=5.5. Top dim: Value at 9.6; weakest: Sentiment at 4.9. No conviction either direction.
The strongest dimensions are Value at 9.6, Technical at 7.2, and Peer rank at 6.8; the weakest are Sentiment at 4.9, Risk (lower is worse) at 5.0, and Insider at 5.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -3.41 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue has declined 91.4% year-over-year and the operating margin has compressed to -982.9%, signaling near-total erosion of the top line and raising value-trap risk that puts the investment case on a fragile foundation.
Trip ifRevenue grows above 0% year-over-year for 2 consecutive quarters, reversing the current decline trajectory.
- P2Three of the most recent four quarters produced positive earnings surprises — including three consecutive beats running through the latest report — suggesting the business is managing costs or generating income ahead of depressed expectations even as revenue contracts.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, ending the current beat streak.
- P3Despite the dramatic top-line contraction, gross margins have held at 47% and the net margin screens in the highest tier — an unusual signal that cost discipline remains intact even as revenue has compressed severely.
Trip ifGross margin falls below 30% for 2 consecutive quarters, indicating cost discipline has broken down.
- P4The stock is trading below its 200-day moving average with a flat slope, and a death cross signal — though described as recovering — flags that the long-term price trend has not yet turned constructive.
Trip ifPrice closes above the 200-day moving average and holds for 4 consecutive weeks, invalidating the downtrend concern.